Pfizer Japan said on July 7 that it has deleted a boxed warning on neuropsychiatric risks cited in the label of the smoking cessation aid Champix (varenicline) after its request for the deletion was approved by a health ministry panel…
To read the full story
Related Article
BUSINESS
- Kissei Slashes Tavneos Sales Forecast after Safety, Data Concerns
August 3, 2026
- Forxiga Exit Weighs on Ono’s Japan Sales, but Boosts Profit
August 3, 2026
- Bayer, JFCR Ink Strategic Oncology R&D Partnership
August 3, 2026
- CSL Debuts Higher-Dose Hizentra Prefilled Syringe in Japan
August 3, 2026
- Taisho Bags Japan Rights to Kaigene’s FcRn Inhibitor KG006
August 3, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





